Dexmedetomidine ameliorates muscle wasting and attenuates the alteration of hypothalamic neuropeptides and inflammation in endotoxemic rats

Minhua Cheng, Tao Gao, Fengchan Xi, Chun Cao, Yan Chen, Chenyan Zhao, Qiurong Li, Wenkui Yu

1 Medical School of Nanjing University, Nanjing, Jiangsu, P.R China, 2 Institute of General Surgery Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, P.R China

Abstract

Dexmedetomidine is generally used for sedation in critically ill, it could shorten duration of mechanical ventilation, ICU stay and lower basic metabolism. However, the exact mechanism of these positive effects remains unknown. Here we investigated the hypothesis that dexmedetomidine could ameliorate muscle wasting in endotoxemic rats and whether it was related to hypothalamic neuropeptides alteration and inflammation. Forty-eight adult male Sprague-Dawley rats were intraperitoneally injected with lipopolysaccharide (LPS) (5 mg/kg) or saline, followed by 50 μg/kg dexmedetomidine or saline administration via the femoral vein catheter (infusion at 5 μg kg⁻¹ hr⁻¹). Twenty-four hours after injection, hypothalamic tissues and skeletal muscle were obtained. Muscle wasting was measured by the mRNA expression of two E3 ubiquitin ligases, muscle atrophy F-box (MAFbx) and muscle ring finger 1 (MuRF-1) as well as 3-methylhistidine (3-MH) and tyrosine release. Hypothalamic inflammatory markers and neuropeptides expression were also detected in all four groups. Results showed that LPS administration led to significant increase in hypothalamic inflammation together with muscle wasting. Increased hypothalamic neuropeptides, proopiomelanocortin (POMC), cocaine and amphetamine-related transcript (CART) and neuropeptides Y (NPY) and decreased agouti-related protein (AgRP) were also observed. Meanwhile dexmedetomidine administration ameliorated muscle wasting, hypothalamic inflammation and modulated the alteration of neuropeptides, POMC, CART and AgRP, in endotoxemic rats. In conclusion, dexmedetomidine could alleviate muscle wasting in endotoxemic rats, and it could also attenuate the alteration of hypothalamic neuropeptides and reduce hypothalamic inflammation.

Introduction

Pain and anxiety are common in critically ill due to intubation, infection, trauma and long-term bedridden. When inappropriately treated, pain and anxiety can cause tachycardia,
immunosuppression, increased oxygen consumption, elevated catecholamine production and metabolism[1]. So it is necessary and beneficial to keep critically ill sedated[2]. Traditional sedative agents may generate unpredictable and prolonged duration of action in critically ill, due to the redistribution and accumulation of active metabolites[3]. Benzodiazepines have also been reported to be associated with increased risk of delirium, coma and respiratory depression[4]. Nowadays many guidelines recommend using non-benzodiazepines, like dexmedetomidine[5]. Dexmedetomidine, a new sedative, can cause analgesia and induce a sedative state similar to physiologic sleep without causing respiratory depression, by acting on α-2 receptors in the locus caeruleus[6]. Besides the benefits of shortening duration of mechanical ventilation and length of ICU stay, dexmedetomidine has also been demonstrated to reduce risk of delirium and hypertension[7,8]. Moreover in our previous study, we found that the addition of dexmedetomidine to analgesia for patients after abdominal operations could enhance recovery of gastrointestinal function, alleviate postoperative pain and lower metabolism[9]. However, the exact mechanism of these positive effects on critically ill is still unknown.

Hypercatabolism exists in most critically ill patients, which contributes to serious complications and increased mortality[10]. Hypercatabolism can induce a major alteration in metabolism, including reduced appetite, increased catabolism and decreased anabolism of fat and proteins, which all lead to the prolonged phase of critical illness[11]. It is worth noting that unlike starvation or malnutrition, these metabolic changes could hardly be corrected by nutrition support alone. Although, much effort, for example glutamine supplement, growth factor treatment and anti-inflammatory lipid administration has been made to deal with the disordered metabolism, the efficacy is far from satisfactory[12,13]. As previously illustrated, protein catabolism and muscle wasting are thought to play an crucial role in the unsatisfactory efficacy of nutrition support and act as an important contributor to morbidity and mortality among all the metabolic alterations[14]. Thus it is urgent to find out the possible mechanism of hypercatabolism and explore new solutions for this dilemma.

Recently accumulative evidences suggested the importance of central nervous system (CNS) in the regulation of metabolism in disease states[15]. It is proved that central administration of several cytokines can recapitulate the response of peripheral LPS stimulation. In addition, Wisse et al. have demonstrated central inflammation was essential to elicit anorexia induced by peripheral LPS stimulation through bone marrow transplant methods[16]. It is also worth noting that dexmedetomidine generates sedative effects by acting on the locus caeruleus area, which is associated with stress response in CNS[1]. The locus caeruleus area is also the main area generating norepinephrine and can act on most areas of CNS, including hypothalamus. The hypothalamic arcuate nucleus (ARC) is considered to be an important site in the CNS to regulate metabolism and energy homeostasis[17], and the melanocortin system within the hypothalamus is recognized to be an important target of inflammation[18]. ARC is composed of two populations of neurons, POMC and AgRP neurons[19]. The former neuron expresses anorexigenic peptides, POMC and CART. POMC can be pyrolysed into α-melanocytestimulating hormone (α-MSH), which derives anorectic effects by binding to type-3 melanocortin receptor (MC3-R) and MC4-R. AgRP neuron expresses orexigenic peptides AgRP and NPY, which could stimulate appetite and decrease metabolism by acting as an inverse agonist of the MC4-R[20]. Both POMC and AgRP neurons are subject to pro-inflammatory cytokines. Studies have shown cytokines including interleukin (IL)-1β and IL-7 could increase POMC mRNA expression and decrease AgRP mRNA expression, which result in weight loss and muscle wasting[21]. Previously, our studies have suggested that hypothalamic peptides and inflammation may have participated in the endotoxemia-induced muscle wasting in rat models[22,23]. Based on this, we assume that apart from sedation and analgesia, dexmedetomidine could modulate metabolism and reduce muscle wasting through hypothalamic...
pathway. This may be another possible mechanism accounting for its positive effects on critically ill.

**Materials and methods**

**Animals**

Fourty-eight adult male Sprague–Dawley rats (250±20 g) were obtained from the Animal Research Center, Jinling Hospital, Nanjing, China. The animals were housed under regular lighting conditions (light cycle 600–1800) in a constant temperature environment(25˚C) with free access to tap water and standard rat pellet chow. All animals used in this experiment were monitored two times a day, including bedding changes, water refill and food supplement.

Before the experiment, rats were given at least 7 days to adapt to the environment. The experimental protocols were approved by the Institutional Animal Care and Use Committee of Nanjing University and Jinling Hospital.

**Study protocol**

Generally, all rats were anesthetized intraperitoneally with phenobarbital sodium (50 mg/kg) and then the femoral artery was cannulated to monitor study drugs. All rats were randomly categorized into four groups: CON (saline control), PF(pair fed), LPS-CON (endotoxemia + saline) and LPS-DEX (endotoxemia + dexmedetomidine), each group containing twelve animals. Animals in LPS-saline and LPS DEX groups were injected intraperitoneally with LPS (5 mg/kg, Escherichia coli serotype 055:B5, Sigma, St.Louis, MO, USA). Thirty minutes thereafter, LPS-DEX group received 50μg/kg dexmedetomidine(Hengrui Medicine Co.LTD, Jiangsu, China) administration via the femoral vein catheter (infusion at 5 μg kg⁻¹ hr⁻¹) and LPS-CON group received equal amount of saline. The CON group were injected intraperitoneally with saline (5 mg/kg). The PF group was a subset of saline-treated rats pair fed to LPS injected rats to eliminate the effects of different food intake on central neuropeptides and inflammation. Due to the reproducibility, controllability and representativeness of LPS injection, it was widely used to study muscle wasting in endotoxemia; thus, we applied this method as previously described[24]. The dexmedetomidine used was short-acting intravenous medicine, mainly within 24 h. The dose of 50μg/kg of dexmedetomidine was chosen based on previous studies of the effects of dexmedetomidine in vivo[22]. After the administration of dexmedetomidine or saline, rats were then put back to the animal facility. Twenty-four hours later, the rats were executed with an overdose of phenobarbital sodium and the hypothalamus tissue was rapidly dissected and kept at -80˚C until analysis. The extensor digitorum longus (EDL) was immediately obtained to measure the proteolytic rate, and the gastrocnemius muscle was harvested and frozen in -80˚C.

**Rate of protein turnover**

To measure protein breakdown rates, as formally described[23], fresh EDL muscles were fixed via the tendons to aluminium wire supports at resting length, and preincubated in oxygenated medium (95% O₂–5% CO₂): Krebs–Henseleit bicarbonate buffer (pH7-4) which contains 5 mM glucose, 0–1 U/ml insulin, 0–1 mM isoleucine, 0–17 mM leucine and 0–20 mM valine. After one hour preincubation, muscles were transferred to fresh medium of identical composition and incubated for a further 2 h with 0–5 mM cycloheximide. The degradation rates of total and myofibrillar proteins were measured by the release in the medium of free tyrosine and 3-methyl-histidine (3-MH) respectively, and expressed as nanomoles of tyrosine/3-MH in medium per 2 h/g/muscle. Muscle was also homogenized in 0–4 mM perchloric acid to
determine tissue-free 3-MH and tyrosine. The net generation of 3-MH was calculated as the amount of 3-MH in the medium minus the decrease in tissue free 3-MH before and after incubation. Net free tyrosine generation was calculated as the amount of tyrosine released into the medium plus the increase in tissue-free tyrosine during incubation. Both tyrosine and 3-MH levels in medium or tissue samples were measured by high-performance liquid chromatography (HPLC).

Double distilled water was used in HPLC. All reagent and water was filtered through a 0.45 μm filter membrane. Derivating agent was prepared the same day it was used. After muscle tissues were thawed, take 200mg into homogeniser with 0.5mL absolute ethyl alcohol and homogenated at a high speed under 4°C for 10min. Followed by centrifugation at 12000rpm for 15min and reserve supernatant for HPLC. Precolumn derivatization, mix 10μl sample or reference standard with 100μl and reaction for 15min at room temperature. Then draw 20μl sample for computer analysis. Moblie phase was 50mmol/L sodium acetate solution, formaldehyde and tetrahydrofuran, of which the proportion of A liquid is 82:17:1 and B liquid is 22:77:1. Column temperature was at 30°C, flow velocity was 1.0mL/min. Excitation and emission wavelength of HPLC fluorescence detector was 338nm and 425nm respectively. Data was acquired and chromatograms were analyzed with Chromeleon 7.2 software.

Analysis of cytokine gene expression in the muscle and hypothalamus tissues

The total RNA was isolated from hypothalamus and gastrocnemius muscle using Trizol reagent (Invitrogen, USA) according to the manufacturer’s instructions. The mRNAs of TNF-α and IL-6 were separately reverse-transcribed to cDNA and measured by real-time quantitative polymerase chain reaction (PCR), which was performed using a Rotor Gene 3000 system (Corbet, Sydney, Australia). Gene expression was analysed using the Rotor-Gene Real-Time Analysis Software 6.1. Glyceraldehyde phosphate dehydrogenase (GAPDH) was used as an internal control gene to normalize the target mRNAs, and gene expression was compared among groups using the DDCT method. The primer sequences are listed in Table 1.

Statistical analysis

The experimental data were expressed as means ± standard error (SE). Statistical analyses were performed using SPSS 21.0 software (SPSS Inc, USA). The comparisons of differences among groups were accomplished by a one-way analysis of variance (ANOVA), with pretreatment (LPS and saline) and treatment (dexmedetomidine and saline) as the main factors, followed by Newman–Keuls post hoc test. Differences were considered statistically significant at P < 0.05.

Results

Rate of protein breakdown and muscle atrophic gene expression

Compared with the control, LPS administration resulted in significant decreased food intake (P < 0.01, Fig 1), loss of body weight (BW) and lower EDL–BW ratio (both P < 0.05, Fig 1). In the PF group, no significant difference in body weight, EDL weight and EDL–BW ratio were observed when compared with the control, indicating that the decreased food intake had very little effect on muscle weight. However, in the group treated with LPS and dexmedetomidine, both weight loss and reduction of EDL-BW ratio were attenuated (P < 0.05 Fig 1). Original data can be seen in S1 Tables.

Muscle protein breakdown was measured by 3-MH and tyrosine release. As expected, when compared with the control, there was a significant increase in the rate of total protein
proteolysis 24 hours after LPS administration (both P < 0.01, Fig 2). Also, significant elevated expression of two atrophic gene, MuRF-1 and MAFbx was observed after LPS administration (P < 0.01, Fig 2). These results confirmed that endotoxemia could induce muscle wasting in animal models. Despite decreased food intake has little effect on muscle wasting in saline pre-treated rats as shown in PF group, dexmedetomidine administration could significantly attenuate total protein breakdown in endotoxemic rats (P < 0.01, Fig 2). Similarly, the mRNA expression of MuRF-1 and MAFbx in endotoxemic rats were significantly reduced when treated with dexmedetomidine (both P < 0.05, Fig 2). Original data can be seen in S1 Tables.

Taken together, these results demonstrated that dexmedetomidine treatment can alleviate the muscle wasting caused by endotoxemia.

Hypothalamic neuropeptides and inflammatory cytokine gene expression

The anorexigenic genes, POMC and CART, expression increased after LPS administration when compared with the control and PF group (both P < 0.05, Fig 3). On the contrary, there was a significant decrease in orexigenic neuropeptide AgRP expression in endotoxemic rats (P < 0.01, Fig 3). However, the expression of another orexigenic neuropeptide, NPY, did not decrease after LPS administration (Fig 3). In the group treated with LPS and dexmedetomidine, downregulated expression of POMC and CART was observed when compared with endotoxemia group (both P < 0.05, Fig 3), although they did not reach the level of control group. Additionally, the reduction of AgRP caused by LPS was reversed (P < 0.01, Fig 3) by dexmedetomidine and showed no significant difference comparing with the control group (P > 0.05, Fig 3). However, dexmedetomidine administration showed little effect on the increased expression of NPY induced by LPS administration (P > 0.05, Fig 3). Original data can be seen in S1 Tables.

Significant elevation of hypothalamic inflammatory markers, IL-1β and TNF-α, were observed after LPS administration when compared with the control (P < 0.01, Fig 4). And dexmedetomidine administration could attenuate the increased hypothalamic inflammation induced by LPS, it is worth noting that the level of TNF-α almost returned to normal (P > 0.05,

Table 1. The primer sequences.

| Gene    | Primers Accession No. | Accession No. |
|---------|-----------------------|---------------|
| MuRF1   | Forward 5' -GGACGGAAATGCTATGGAGA-3' Reverse 5' -AACGACCTCCAGACATGGG-3' | NM_080903.1  |
| MAFbx   | Forward 5' -CCATCAGAAAATGGATCTCATGTT-3' Reverse 5' -AGCACGTGAACCCCTTTCCG-3' | NM_133521.1  |
| POMC    | Forward 5' -GCCGTTCACAGACATGTCAC-3' Reverse 5' -GGCTGTCAACAGACATGTCAC-3' | NM_139326.2  |
| AgRP    | Forward 5' -TGAAAGGGCCTCAAGAGGT-3' Reverse 5' -CACAGTCCAGACAGGT-3' | NM_033650.1  |
| CART    | Forward 5' -CCGAGCTGCTGACATCTA-3' Reverse 5' -GGATGTCGCTGACAGTACTG-3' | NM_017110.1  |
| NPY     | Forward 5' -CTGACCCCTGCTCTATCC-3' Reverse 5' -GGTCTTCAGACATGTCGCTT-3' | NM_012614.2  |
| IL-1β   | Forward 5' -TTCAAAATCTCACAGGAGCAT-3' Reverse 5' -AGGTCTGTCATCATCCGAC-3' | NM_031512.1  |
| TNF-α   | Forward 5' -CCACGGCTTCTCTGTACTTG-3' Reverse 5' -GCTACGGCTGCGTGCTGTC-3' | NM_012675.3  |
| GAPDH   | Forward 5' -GCGAGCTGACAGCTCCGACACG-3' Reverse 5' -GCCAGTAGACTCCAGACAGAT-3' | NM_017008.4  |

https://doi.org/10.1371/journal.pone.0174894.t001
Fig 4. Original data can be seen in S1 Tables. These results indicated that dexmedetomidine might have a hypothalamic anti-inflammatory effect in endotoxemic rats.

**Discussion**

It is well known that many factors could influence metabolism. For example, metabolism would elevate under the circumstances of pain or anxious. Due to intubation, infection, trauma and long-term bedridden, pain and anxiety exist in most critically ill patients. When inappropriately treated, pain and anxiety can cause many negative effects, so it is necessary and beneficial to keep critically ill patients sedated[2]. Compared with traditional benzodiazepine sedatives, non-benzodiazepines, like midazolam and dexmedetomidine, may be more applicable and safer[5].
Dexmedetomidine is a highly selective α-2 adrenoreceptor agonist providing sedative and anxiolytic activity via receptors within the locus ceruleus, analgesia via receptors in the spinal cord, and attenuation of the stress response with no significant respiratory depression\[6\]. It proved to be safer by causing fewer adverse effects and could reduce cardiac output and hepatic blood flow, potentially increasing its action duration in critically ill patients\[25\]. Although dexmedetomidine was generally used for sedation in critically ill patients, our previous clinical study found that applying dexmedetomidine to postoperative patients could accelerate the recovery of gastrointestinal function and lower metabolism\[11\]. However, the exact mechanism of dexmedetomidine’s positive effects on critically ill patients remains unknown. Here we first
demonstrated that dexmedetomidine treatment could reduce endoxemia-induced muscle wasting and is associated with the alteration of hypothalamic peptides and inflammation.

As shown in the present study, dexmedetomidine administration significantly reduced the release of 3-MH and tyrosine and decreased the expression of two important muscle atrophy gene in endotoxemic rats, MuRF-1 and MAFbx. In other words, endotoxemic muscle wasting was attenuated. Richard and others demonstrated that dexmedetomidine-treated patients spent less time on mechanical ventilation[26]. Prolonged mechanical ventilation in critically ill patients was considered to be associated with the atrophy of respiratory muscles, including

Fig 3. Effects of dexmedetomidine(DEX) and saline treatment on the expression of hypothalamic neuropeptides, POMC, CART, AgRP and NPY, in control, septic and treated (with DEX or saline) rats. Hypothalamic genes expression were measured by real-time PCR. GAPDH was used as control. All the mRNA expressions were normalized to those of control group. Significant data measured from control were labelled (*) with P-values < 0.05. Significant data measured from sepsis group was labelled (#) with P-values <0.05. https://doi.org/10.1371/journal.pone.0174894.g003
intercostal muscles, diaphragm, and the abdominal muscles. With combination of our results, dexmedetomidine alleviating endoxemia-induced muscle wasting could be one of the important mechanism for its ability to shorten duration of mechanical ventilation in critically ill.

However, the underlying mechanism of dexmedetomidine’s ability to reduce endotoxemic muscle wasting was undefined so far. Dexmedetomidine generates sedative effects by acting
on the locus caeruleus area, which is associated with stress response in the brain[1]. And the locus caeruleus area is the main area generating norepinephrine and can act on most sites in the CNS, including hypothalamus. So we assume that dexmedetomidine may have the effect of metabolic modulation through hypothalamic pathway and here we first determined the hypothalamic effect of dexmedetomidine in endotoxemic models. In the present study, we found that in endotoxemic rats, dexmedetomidine could attenuate the alterations of hypothalamic peptides, accompanied by lower skeletal muscle wasting. These results indicated dexmedetomidine attenuating muscle wasting might be associated with the regulation of hypothalamic neuropeptides. The exact mechanism of how dexmedetomidine regulated neuropeptides in endotoxemia still needed further investigation.

Pro-inflammatory cytokines, endothelium-released oxygen radicals and complement factors contributed to the systemic inflammation in endotoxemic or septic states. In the past, peripheral inflammation was considered as a major factor accounting for muscle wasting or even organ dysfunction[27]. However, clinical trials with administration of TNF-α antibody or steroids showed negative results in septic patients[28,29], indicating that peripheral inflammation may not be as important as we used to think in the process. Meanwhile, there are emerging studies suggested that inflammation in the CNS may play a more important role in the endotoxemic or septic muscle wasting and negative energy balance than peripheral inflammation[30,31]. In our study, LPS administration resulted in increased hypothalamic inflammatory cytokines, which was in consistent with previous studies.

The constant hypothalamic inflammation could have a negative impact on the energetic balance mainly through the melanocortin system. A series of studies have shown that the melanocortin system was involved in the regulation of malignant consumption or even cachexia. While the cachexia syndrome could be ameliorated by blocking MC4-R signalling using genetic or pharmacological methods in renal failure, cardiac disease and acute LPS injection[32]. Moreover, reduced muscle wasting was observed after administration of AgRP, the antagonist of MC4-R, in the animal model of chronic kidney disease (CKD)[33]. Thus on the other hand, the decreased endotoxemia-induced muscle wasting observed in the present study could be the result of neuropeptides alteration induced by central inflammation.

In the endotoxemia group in our study, the hypothalamic inflammation was also related to the alterations of the mRNA expression of POMC and AgRP, which was consistent with former studies[25]. It has been proved that POMC and AgRP neurons both expressed IL-1 receptors, making the two neurons subject to inflammatory cytokines[30]. Thus stimulated by IL-1β, which was be activated in endotoxemic or septic central inflammation, increased POMC and decreased AgRP expression were observed. This was further supported by the present results.

As a matter of fact, in addition to sedation, dexmedetomidine can reduce systemic inflammation significantly[25], which could also account for the benefits observed after dexmedetomidine administration in critically ill with sepsis. In the present study, we found that hypothalamic inflammation was attenuated after dexmedetomidine administration, which may contribute to the neuropeptides alteration. Apart from acting on the locus caeruleus area [1], the transportation of dexmedetomidine from blood circulation to CNS was elevated in septic models due to increased permeability of blood brain barrier. Thus, the anti-inflammation effect of dexmedetomidine was very likely to be achieved in the CNS. Hypothalamic inflammation could lead to muscle degradation and atrophy[31], mainly through the melanocortin system, so the regulative effect of dexmedetomidine on hypothalamic neuropeptides may also contribute to the alleviated muscle wasting in endotoxemia and its ability to shorten duration of mechanical ventilation in critically ill.
Hypercatabolism exists in most critically ill patients with severe trauma, burn or sepsis, which contributes to the prolonged mechanical ventilation, infection and ICU stay in critically ill. Muscle wasting was considered to be the main characteristic of hypercatabolism and could result in severe complications and increase mortality[33]. Many interventions, including early enteral nutrition and trophic enteral feeding[34,35] have been proposed to deal with this dilemma, the effect was still unsatisfactory. Recently, Puthucheary et al. have demonstrated that muscle wasting in critically ill raised on admission and remained high during the first week of ICU stay[20]. More importantly, the alteration in timing and type of nutrition had little or no effect and, even could aggravate the acute muscle loss in some cases[11]. Mechanism studies have shown that increased protein degradation other than decreased protein synthesis, counted for muscle wasting[20].

Here we found that dexmedetomidine could alleviate endotoxemia-induced muscle wasting and affect hypothalamic peptides simultaneously, which could be interpreted as an important complementary mechanism of dexmedetomidine’s positive effects on critically ill. Moreover, this could provide a new perspective to solve the problem of hypercatabolism and improve the effect of nutritioanl support in critically ill patients. In the future, we should pay more attention to the CNS conditions to evaluate metabolism in septic patients in clinical practise. Or perhaps combining with central-oriented pharmaceuticals, dexmedetomidine administration may achieve better results. But all of these presumptions need further investigations to validate.

Although here we demonstrated that dexmedetomidine may attenuate muscle wasting through a central circuit, there were some limitations. Firstly, we only utilized peripheral dexmedetomidine administration to investigate its central action. Despite the resemblance of clinical practice, it was compromised when compared with central administration. Secondly, as a sedative drug, dexmedetomidine can reduce activity, alleviate pain and anxiety, which could all lead to lower metabolism directly. So the role that hypothalamic neuropeptides played may not completely account for the reduced muscle wasting we observed. Thirdly, we only investigated the effect of dexmedetomidine on hypothalamus and muscles at 24 h after LPS injection. Longer time effect is required in the future studies. Also, detailed molecular pathway is needed to show the exact mechanism of dexmedetomidine’s effect on central melanocortin system under septic conditions.

**Conclusions**

In conclusion, dexmedetomidine could reversing muscle wasting, and it could also attenuate the alteration of hypothalamic neuropeptides and reduce hypothalamic inflammation. This expanded the usage of dexmedetomidine in critically ill besides sedation. The exact mechanism for dexmedetomidine’s central effect on endotoxemia-induced muscle wasting requires further exploration. These results may provide a new perspective for the research and management of muscle wasting in critically ill patients and the study of dexmedetomidine effect.

**Supporting information**

S1 Tables.
(DOCX)

**Acknowledgments**

Author Minhua Cheng contributed to the conception and design of the study, literature research and article drafting. Wenkui Yu and Qiurong Li contributed to literature research
and language assistance. Tao Gao, Fengchan Xi, Chun Cao, Yan Chen and Chenyan Zhao helped conducting the experiment and tests. All authors have approved the final version to be submitted.

**Author Contributions**

**Conceptualization:** MHC WKY.
**Data curation:** MHC.
**Formal analysis:** MHC.
**Funding acquisition:** WKY.
**Investigation:** TG FCX YC.
**Methodology:** MHC CC YC.
**Project administration:** TG.
**Resources:** MHC CYZ.
**Software:** CC.
**Supervision:** WKY QRL.
**Validation:** TG.
**Visualization:** MHC.
**Writing – original draft:** MHC.
**Writing – review & editing:** TG WKY.

**References**

1. Guo TZ, Jiang JY, Buttermann AE, Maze M. Dexmedetomidine injection into the locus ceruleus produces antinociception. Anesthesiology. 1996; 84:873–881. PMID: 8638842
2. Riker RR, Fraser GL. Altering intensive care sedation paradigms to improve patient outcomes. Crit Care Clin. 2009; 25:527–538. https://doi.org/10.1016/j.ccc.2009.05.004 PMID: 19576528
3. Gravel NR, Searle NR, Sahab PG. Sedation in critically ill patients: practical recommendation. CNS Drugs. 1999; 11:9–22.
4. Ho KM, Ng JY. The use of propofol for medium and long-term sedation in critically ill patients: a meta-analysis. Intensive Care Med. 2008; 34: 1969–1979. https://doi.org/10.1007/s00134-008-1186-5 PMID: 18575838
5. Barr J, Fraser GL, Punttilo K, Ely EW, Gélinas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Critical care medicine. 2013; 41(1):263–306. https://doi.org/10.1097/CCM.0b013e3182783b72 PMID: 23269131
6. Aantaa R, Kallio A, Virtanen R. Dexmedetomidine, a novel α2-adrenergic agonist: a review of its pharmacodynamic characteristics. Drugs Future. 1993; 18:49–56.
7. Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007; 298(22):2644–2653. https://doi.org/10.1001/jama.298.22.2644 PMID: 18073360
8. Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care. 2000; 4: 302–308. https://doi.org/10.1186/cc712 PMID: 11056756
9. Cheng M, Shi J, Gao T, Shen J, Zhao C, Yu W. The Addition of Dexmedetomidine to Analgesia for Patients After Abdominal Operations: A Prospective Randomized Clinical Trial. World Journal of Surgery. 2016(Epub).
10. Angus DC, Linde-Zwirble WT, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine. 2001; 29, 1303–1310. PMID: 11445675

11. Casaer MP, Van den Bergh. Nutrition in the acute phase of critical illness. N Engl J Med. 2004; 370:1227–1236.

12. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360:1283–1297. https://doi.org/10.1056/NEJMoa0810625 PMID: 19183834

13. Zheng Y, Hu FB, Ruiz-Canela M, Clish CB, Dennis C, Salas-Salvado J, et al. Metabolites of Glutamate Metabolism Are Associated With Incident Cardiovascular Events in the PREDIMED PREvención con Dita MEDiterránea (PREDIMED) Trial. Journal of the American Heart Association. 2016, 5(9).

14. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010; 142:531–543. https://doi.org/10.1016/j.cell.2010.07.011 PMID: 20723755

15. Moldawer LL, Svaninger G, Gelin J, Lundholm KG. Interleukin 1 and tumor necrosis factor do not regulate protein balance in skeletal muscle. Am J Physiol. 1987; 253:C766–C773. PMID: 3501247

16. Wisse BE, Ogimoto K, Tang J, Harris MK Jr, Raines EW, Schwartz MW. Evidence that lipopolysaccharide-induced anorexia depends upon central, rather than peripheral, inflammatory signals. Endocrinology. 2007; 148:5230–5237. https://doi.org/10.1210/en.2007-0394 PMID: 17673516

17. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature. 2006; 443(7109):289–295. https://doi.org/10.1038/nature05026 PMID: 16988703

18. Arora Sarika, Anubhuti. Role of neuropeptides in appetite regulation and obesity-a review. Neuropeptides 2006; 40:375–401. https://doi.org/10.1016/j.npep.2006.07.001 PMID: 16935329

19. Oyama LM, do Nascimento CM, Carriers J, de Piano A, Tock L, Sanches Pde L, et al. The role of anorexigenic and orexigenic neuropeptides and peripheral signals on quartiles of weight loss in obese adolescents. Neuropeptides. 2010; 44:467–474. https://doi.org/10.1016/j.npep.2010.07.002 PMID: 20709393

20. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayeke G, Chan P, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013; 310:1591–1600. https://doi.org/10.1001/jama.2013.278481 PMID: 24108501

21. Scarlett JM, Zhu X, Enriori PJ, Bowe DD, Batra AK, Levasseur PR, et al. Regulation of agouti-related protein messenger ribonucleic acid transcription and peptide secretion by acute and chronic inflammation. Endocrinology. 2008; 149:4837–4845. https://doi.org/10.1210/en.2007-1680 PMID: 18583425

22. Xu Li, Bao Hongguang, Si Yanna, Wang Xiaoliang. Effects of dexmedetomidine on early and late cytokines during polymicrobial sepsis in mice. Inflamm Res. 2013 May; 62(5):507–14. https://doi.org/10.1007/s00011-013-0604-5 PMID: 23463181

23. Duan K, Yu W, Lin Z, Tan S, Bai X, Gao T, et al. Insulin ameliorating endotoxaemia-induced muscle wasting is associated with the alteration of hypothalamic neuropeptides and inflammation in rats. Clinical endocrinology. 2015; 82(5):695–703. https://doi.org/10.1111/cen.12610 PMID: 25204980

24. Taniguchi Takumi, Kidani Yoko, Kanakura Hiroko, Takemoto Yasuhiko, Yamamoto Ken. Effects of dexmedetomidine on mortality rate and inflammatory response to endotoxin-induced shock in rats. Crit Care Med. 2004 Jun; 32(6):1322–6.29. PMID: 15187514

25. Jen A Tan, Kwok M Ho. Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med. 2010; 36:926–939. https://doi.org/10.1007/s00134-010-1877-6 PMID: 20376429

26. Venn R M, Grounds RM. Dexmedetomidine vs. Propofol for Short-Term Sedation of Postoperative Mechanically Ventilated Patients. British Journal of Anaesthesia. 2001; 87(5):684–90. PMID: 11878517

27. Fanzani A, Conraads VM, Penna F, Martinet W. Molecular and cellular mechanisms of skeletal muscle atrophy: an update. Journal of Cachexia, Sarcopenia and Muscle. 2012; 3;:163–179. https://doi.org/10.1007/s13539-012-0074-6 PMID: 22673968

28. Iark MA, Plank LD, Connolly AB, Streat SJ, Hill AA, Gupta R, et al. Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis—a randomized, clinical trial. Critical Care Medicine. 1998; 26:1650–1659. PMID: 9781721

29. Casserly B, Gerlach H, Phillips GS, Lemeshow S, Marshall JC, Osborn TM, et al. Low-dose steroids in adult septic shock: results of the surviving sepsis campaign. Intensive Care Medicine. 2012 Dec; 38 (12):1946–54. https://doi.org/10.1007/s00134-012-2720-z PMID: 23064466
30. DeBoer M.D. Update on melanocortin interventions for cachexia: progress toward clinical application. Nutrition. 2010; 26: 146–151. https://doi.org/10.1016/j.nut.2009.07.003 PMID: 20004082

31. Thaler JP, Choi SJ, Schwartz MW, Wisse BE. Hypothalamic inflammation and energy homeostasis: resolving the paradox. Frontiers in Neuroendocrinology. 2010; 31:79–84. https://doi.org/10.1016/j.yfme.2009.10.002 PMID: 19822168

32. Krasnow SM, Marks DL. Neuropeptides in the pathophysiology and treatment of cachexia. Curr Opin Support Palliat Care. 2010; 4:266–271. https://doi.org/10.1097/SPC.0b013e32833e48e7 PMID: 20733497

33. Cheung WW, Mak RH. Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease. American Journal of Physiology Renal Physiology. 2012; 303:F1315–F1324. https://doi.org/10.1152/ajprenal.00341.2012 PMID: 22914778

34. Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 2011; 365: 506–517. https://doi.org/10.1056/NEJMoa1102662 PMID: 21714640

35. Rice TW, Wheeler AP, Thompson BT, Steingrub J, Hite RD, Moss M, et al. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA. 2012; 307:795–803 https://doi.org/10.1001/jama.2012.137 PMID: 22307571